NCT00000981View on ClinicalTrials.gov

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1993

Conditions
Cytomegalovirus InfectionsHIV Infections
Interventions
DRUG

Fiacitabine

Trial Locations (4)

20892

Natl Institute of Health, Bethesda

35294

Univ of Alabama at Birmingham, Birmingham

98122

Univ of Washington / Madison Clinic, Seattle

921036325

Univ of California / San Diego Treatment Ctr, San Diego

Sponsors

Collaborators (1)

Oclassen Pharmaceuticals
All Listed Sponsors
collaborator

Oclassen Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000981 - The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS | Biotech Hunter | Biotech Hunter